NASDAQ
45.37USD
-0.03 (-0.07%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.8B
P/E
—
EPS
—
Beta
2.20
52W range
7.78-47.84
Day range
45.10–46.87
Open
46.12
Prev close
45.40
Volume
471.9K
Avg volume
707.7K
Dividend
0.00
IPO
2018-10-04
https://www.proactiveinvestors.co.uk/companies/news/1095755 · 7/21/2026+0.50
https://www.proactiveinvestors.co.uk/companies/news/1095751 · 7/21/2026+0.60
https://www.proactiveinvestors.co.uk/companies/news/1095607 · 7/17/2026+0.60
https://www.accessnewswire.com/newsroom/en/metals-and-mining/empress-announces-acquisition-of-north-american-royalty-portfolio-1189219 · 7/10/2026+0.30
https://www.newsfilecorp.com/release/299160/PDD-Holding-Inc.-Shareholders-Are-Encouraged-to-Reach-Out-to-Johnson-Fistel-for-More-Information-About-Potentially-Recovering-Their-Losses · 5/27/2026-0.50
https://www.proactiveinvestors.co.uk/companies/news/1091696 · 5/5/2026+0.80
https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-pipeline-advances-and-ksi-101-clinical-data-including-results-from-a-mesi-cohort-in-a-tertiary-care-uveitis-practice-at-upcoming-scientific-conferences-302759852.html · 5/1/2026+0.80
https://www.proactiveinvestors.co.uk/companies/news/1090769 · 4/18/2026+0.90
https://www.proactiveinvestors.co.uk/companies/news/1090495 · 4/14/2026+0.90
https://www.fool.com/coverage/filings/2026/03/09/investment-firm-doubles-down-on-biotech-stock-adds-386-000-shares-according-to-recent-sec-filing/ · 3/9/2026+0.60
https://www.defenseworld.net/2026/02/16/kodal-minerals-lonkod-shares-down-0-4-heres-what-happened.html · 2/16/2026-0.20
https://www.defenseworld.net/2025/12/28/kodiak-sciences-nasdaqkod-shares-down-5-8-whats-next.html · 12/28/2025-0.60
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
